{"id":"vrvg-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VRVg-2 is a live attenuated rotavirus vaccine that stimulates both humoral and mucosal immune responses against rotavirus antigens. By inducing protective antibodies and cellular immunity, the vaccine aims to prevent rotavirus infection and severe gastroenteritis, particularly in infants and young children in resource-limited settings.","oneSentence":"VRVg-2 is a recombinant rotavirus vaccine candidate designed to prevent rotavirus gastroenteritis through immunization.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:54.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VRVg-2","genericName":"VRVg-2","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"VRVg-2 is a recombinant rotavirus vaccine candidate designed to prevent rotavirus gastroenteritis through immunization. Used for Prevention of rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}